FDA Q-Submission Readiness Calculator

Teams lose weeks when they request FDA feedback before their package is decision-ready. This calculator helps you estimate your readiness score, question quality score, and likely meeting efficiency before you submit a Pre-Sub package. It is built for regulatory leaders, founders, quality managers, and clinical teams who need a disciplined way to de-risk early FDA interactions.

Why This Calculator Exists

In many organizations, Pre-Sub planning is treated as a scheduling task instead of a strategy task. Teams assume they are ready because a slide deck exists and a few regulatory questions are drafted. Then FDA feedback arrives and reveals the true issue: weakly scoped questions, thin test rationale, or unresolved risk logic. This is where timelines slip. The purpose of this calculator is to force explicit scoring around the quality of the submission package rather than the confidence level of the loudest stakeholder.

High-performing teams use Q-Submissions to reduce uncertainty before major spend. They ask FDA questions that can change program architecture, not questions that could be answered internally by reading guidance. They also submit enough technical context for FDA reviewers to provide meaningful direction. If the package is too early, the meeting can produce broad feedback that is hard to action. If it is too late, the organization already committed to test plans and design choices that are expensive to reverse. Your readiness score helps identify that middle zone where FDA interaction is most valuable.

The calculator outputs are not regulatory decisions. They are management indicators. A low readiness score means your team should finish key evidence or tighten questions before requesting FDA time. A mid-range score usually indicates that your package can proceed if you explicitly bound the meeting goals. A high score suggests that the submission is likely to produce higher-value feedback and reduce rework in your 510(k), De Novo, or IDE pathway planning. In practical terms, this helps leadership decide whether to spend another two to four weeks on package quality or move immediately to meeting request submission.

How To Interpret The Scores

Readiness Score

The readiness score combines question clarity, evidence maturity, and team alignment. Scores above 80 usually indicate that questions are specific, evidence is directionally adequate, and internal functions agree on decision criteria. Scores between 60 and 79 can still be workable, but only if the questions are tightly prioritized and assumptions are documented. Scores below 60 generally mean your team will benefit from refining the package first, especially if you expect FDA to comment on testing strategy, risk controls, software documentation depth, or clinical plans.

Question Quality

Question quality focuses on whether FDA can answer in a bounded way. Strong questions describe context, state the proposed approach, and request feedback on a clear decision point. Weak questions ask broad open-ended guidance that is difficult for reviewers to answer precisely in a meeting format. If your question quality score is low, the simplest fix is rewriting each question into a decision frame: current plan, alternatives considered, and specific agency input requested.

Estimated Iterations

Iterations estimate how many cycles of package revision you may need before achieving decision-grade meeting value. One iteration indicates strong preparation and low ambiguity. Two iterations usually indicate moderate risk and manageable gaps. Three or more iterations signals broad uncertainty, often caused by unclear indications, incomplete performance rationale, or weak cross-functional alignment. This metric is useful for staffing because iteration cycles consume regulatory writing, R&D, quality, and clinical bandwidth.

Operational Playbook For Better Q-Sub Packages

First, define one primary objective for the meeting. Teams that pursue five objectives in one package usually dilute outcomes. Examples of strong single objectives include: alignment on bench test matrix acceptance criteria, agreement on cybersecurity documentation depth, or feedback on clinical evidence threshold for a new intended use claim. Once the objective is fixed, your questions become easier to prioritize and your background section becomes more coherent.

Second, align regulatory and engineering language early. Many Q-Sub failures come from internal translation gaps: engineering believes evidence is complete while regulatory sees missing rationale linkage to safety and effectiveness. Build a simple one-page trace map linking intended use, key risks, controls, verification evidence, and open decisions. This trace map improves both your internal prep and FDA discussion quality because reviewers can see the logic chain behind your requests.

Third, pressure-test the package with a mock reviewer session. Assign one person to argue that your plan is under-justified, and another to challenge your predicate or pathway assumptions. Capture every point that cannot be answered with current evidence. Those points become either package improvements or explicit meeting questions. This process turns hidden assumptions into actionable edits and often improves question quality score by two or more points.

Fourth, cap the question set. More questions do not mean better outcomes. Most teams get higher value by limiting primary questions to four through eight and placing secondary items in a written feedback appendix. In live discussions, fewer questions create space for follow-up depth. Depth is what produces usable agency direction. If you include too many topics, FDA responses can stay high-level and force additional cycles later.

Fifth, define post-meeting decision triggers before the meeting happens. Decide in advance what kind of FDA feedback will trigger changes in test strategy, clinical planning, or submission timing. This avoids post-meeting drift and accelerates execution. The most effective teams leave the meeting with pre-assigned owners for each action item and with deadlines tied to the next regulatory milestone.

Keyword Research Snapshot (US, checked April 2, 2026)

This page targets active search intent around pre-submission planning and provider comparisons. We selected the topic cluster from live query reviews and trend checks, then mapped content and tool sections to those intents. Core phrases include "FDA pre-submission meeting," "Q-Submission consultant," "medical device pre-sub checklist," and "how to prepare for FDA Pre-Sub."

Why this matters: pages that align with explicit intent convert better because visitors arrive with a specific planning problem. In this case, users are not looking for broad FDA education; they are looking for practical readiness planning, timeline control, and provider selection guidance. That is why this page combines a calculator, implementation framework, and internal links to adjacent tools.

When To Use External Support

If your product team has limited in-house Q-Sub experience, external support can materially reduce preventable delay. Support is most valuable when indications are novel, software risk posture is nontrivial, or clinical strategy is under debate. The objective is not to outsource accountability; it is to improve package quality and decision speed. Use provider comparisons to evaluate practical capability: similar device history, quality of technical writing, response discipline, and ability to align with your internal team rhythm.

Compare providers by evidence, not branding. Ask for anonymized examples of question framing, risk rationale narratives, and test strategy briefs. Ask how they handle disagreement between regulatory and engineering teams. Ask how they de-risk meeting follow-through after feedback arrives. A provider that only delivers polished slides without decision-grade structure can still leave your team exposed to rework. A provider with strong operating cadence can reduce iteration count and compress time to submission readiness.

FAQ

Is this an FDA-approved scoring model?

No. This tool is an operational planning model for internal readiness management. Use it to structure decisions and improve package quality before submission.

What readiness score should we target?

Most teams should target at least 75 before requesting a meeting. Programs with novel technology or unresolved risk logic should target 80+ to reduce follow-up cycles.

How many questions should we include in a Pre-Sub package?

Usually four to eight primary questions. Keep secondary or exploratory items in an appendix to preserve depth in meeting discussion.

Should we wait for all testing to finish?

Not always. You should wait for enough evidence to support meaningful dialogue on the decisions you are asking FDA to inform. Full completion of all testing is not required for every Pre-Sub objective.

Citations

• FDA: Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
• FDA: eSTAR (electronic Submission Template and Resource)
• eCFR 21 CFR Part 807 Subpart E (Premarket Notification)
• FDA: Premarket submissions and interactions guidance hub
• Google Trends US: query cluster used for topic validation
• Google Search query: "FDA pre-submission meeting"
• Google Search query: "Q-Submission medical device consultant"